Navigation Links
Signalife Establishes Signalcare Division
Date:2/14/2008

LOS ANGELES, Feb. 14 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has established a division focused on developing, acquiring and/or testing therapies capable of treating cardiovascular disease at an earlier state and in a more effective manner.

From experience gained and relationships developed through the deployment of its award-winning Fidelity 100 Heart Monitor - including extensive utilization of the Fidelity 100 at this year's Super Bowl in Glendale, Arizona -- the Company has already learned significant details regarding the relationship between earlier and more accurate cardiovascular monitoring, on the one hand, and effective cardiovascular treatment-oriented technologies, on the other hand.

Dr. Lowell Harmison, the Company's President and Chief Executive Officer, commented that "more effective heart monitoring can be used to validate or invalidate technologies that, before now, were unable to be properly vetted. Through the use of our suite of heart monitoring devices and technologies, we believe that it is time to assist in moving the treatment of cardiovascular disease to earlier, less invasive and more predictable methodologies."

The Company has divisionalized Signalcare for the time being, and will evaluate placing Signalcare into a wholly-owned subsidiary after developments and relationships have materialized or have become formalized.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Signalife to Deploy Fidelity 100 Heart Monitors for AFL
2. LifeNet Health Establishes The Skin & Wound Allograft Institute
3. Carnegie Mellon Establishes Ray and Stephanie Lane Center for Computational Biology
4. AT&T Establishes New Network Services for Leading Medical Liability Insurer
5. Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation
6. Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service
7. Nunez Health Reform Bill Establishes Mandatory Purchase Without Linking to Subsidies for Middle Class and Poor
8. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
9. CIG Corp. Establishes a Medical Advisory Board
10. MM2 Group Establishes New Venture for Sofgel Manufacture in China
11. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: